Newron Pharmaceuticals SpA (SWX:NWRN, ETR:NP5) CEO Stefan Weber speaks to Proactive s Thomas Warner about what the investors can expect from Newron during.
Thomas-warner
Stefan-weber
Newron-pharmaceuticals-sp
Newron-pharmaceuticals-spa
Newron announces results of explanatory studies with evenamide in healthy volunteers and patients with schizophrenia
Newron Pharmaceuticals SpA / Key word(s): Miscellaneous
01-Apr-2021 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.
Primary objective of safety of evenamide met on all safety variables for study 010 in healthy volunteers and study 008 in patients with schizophrenia
Additional safety and efficacy study 008A in therapeutic dose (30 mg BID) to start in April 2021
Milan, Italy and Morristown, NJ, USA, April 1, 2021 - Newron Pharmaceuticals S.p.A. ( Newron ) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced initial results from two short-term explanatory studies in evenamide: study 010 in healthy volunteers an
Bresso
Lombardia
Italy
Germany
Australia
Japan
Milan
United-states
India
United-kingdom
Brazil
Colombia